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Alzheimer’s dementia: randomized double-
blind, placebo and active controlled
adaptive trial and open-label extension
Laura M. Gault1*, Robert A. Lenz1,2, Craig W. Ritchie3, Andreas Meier4, Ahmed A. Othman1,5, Qi Tang1, Scott Berry6,
Yili Pritchett1,7 and Weining Z. Robieson1Abstract
Background: Results from a phase 2a study indicated that treatment with the novel α7 nicotinic acetylcholine
receptor agonist ABT-126 25 mg once daily (QD) was associated with a trend for improvement in cognition in
subjects with mild-to-moderate Alzheimer’s dementia (AD). A phase 2b program was designed to evaluate a
broader dose range of ABT-126 as monotherapy in subjects with mild-to-moderate AD. The program consisted of a
double-blind, placebo and active controlled study of ABT-126 (dose range 25–75 mg) and an open-label extension
study (75 mg).
Methods: The randomized double-blind study enrolled 438 subjects (Mini-Mental Status Examination score of
10–24, inclusive) not currently taking acetylcholinesterase inhibitors or memantine. Subjects received 24 weeks of
ABT-126 25 mg QD (n = 77), ABT-126 50 mg QD (n = 108), ABT-126 75 mg QD (n = 73), donepezil 10 mg QD (n = 76),
or placebo (n = 104). The primary endpoint was the change from baseline to week 24 in the 11-item Alzheimer's
Disease Assessment Scale—Cognitive subscale (ADAS-Cog) total score. Subjects completing the double-blind study
could enroll in the 28-week open-label extension study. Adverse events (AEs) and other safety parameters were
monitored in both studies.
Results: A total of 367 patients (83.8 %) completed the double-blind study and 349 (79.7 %) entered the open-label
study. Compared with placebo, donepezil significantly improved ADAS-Cog 11-item total scores from baseline to
week 24 (−2.29 ± 0.95; one-sided P = 0.008). No ABT-126 dose demonstrated a statistically significant improvement vs
placebo at week 24 in the ADAS-Cog total score: ABT-126 25 mg, −0.47 ± 0.94 (P = 0.309); ABT-126 50 mg, −0.87 ± 0.85
(P = 0.153); and ABT-126 75 mg, −1.08 ± 0.94 (P = 0.127). Rates of serious AEs and discontinuations due to AEs were
similar across treatment groups. The most frequently reported AEs in both studies were constipation, fall, and
headache. No clinically meaningful changes were observed in other parameters.
Conclusions: In the double-blind trial, donepezil significantly improved ADAS-Cog scores but no statistically
significant improvement was seen with any ABT-126 dose. ABT-126 had an acceptable safety profile in
subjects with mild-to-moderate AD in both studies.
Trial registration: ClinicalTrials.gov NCT01527916, Registered 3 February 2012 (randomized trial). ClinicalTrials.
gov NCT01676935. Registered 29 August 2012 (open-label extension study).
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Alzheimer’s dementia (AD) is a neurodegenerative dis-
order currently affecting nearly 5 million adults over the
age of 65 years in the United States, a number that is ex-
pected to significantly increase over the next 40 years
[1]. The few available marketed products, acetylcholin-
esterase inhibitors (AChEIs) and N-methyl-D-aspartate
receptor antagonists, provide transient and modest im-
provements in cognition. Even when disease-modifying
treatments are available to slow the course of the degen-
erative process, a need will remain for symptomatic
treatments for patients with mild-to-moderate dementia.
A novel approach to symptomatic treatment for AD is
modulation of the α7 nicotinic acetylcholine receptors
(nAChRs), acetylcholine-gated cation channels found in
areas of the brain that are important for learning and
memory [2]. Activation of α7 nAChRs leads to an influx
of calcium and activation of second messenger systems,
and ultimately a release of a number of other neuro-
transmitters important for cognition [3]. The mechanism
of action of α7 nAChR agonists is expected to differ
from marketed compounds such as AChEIs that inhibit
the enzyme which degrades acetylcholine in the synaptic
cleft, resulting in an increased effect from acetylcholine
at all receptor subtypes. By eliminating the dose-limiting
toxicity associated with AChEIs acting at muscarinic and
other nAChR subtypes that are not procognitive yet me-
diate untoward side effects [4], the efficacy and side-
effect profiles of α7 nAChR agonists may differ from
AChEIs [5]. Several α7 nAChR partial agonists have
shown potential in the treatment of AD [6, 7] but either
the procognitive effects were not reproducible [8] or the
trials are currently on clinical hold, apparently due to
safety concerns related to gastrointestinal side effects [9].
ABT-126 is a potent α7 nAChR agonist that displayed
high affinity (Ki = 12–14 nM) at human, rat, and mouse
α7 nAChRs in nonclinical studies. The in-vitro selectiv-
ity profile of ABT-126 was evaluated in a battery of radi-
oligand binding assays (Cerep, France) that contained
representatives of G-protein-coupled receptors and lig-
and/voltage-sensitive ion channels. In these assays, ABT-
126 10 μM showed little binding, with the exception of
the 5-HT3 receptor. ABT-126 had a Ki value of 140 nM
(n = 6) at the 5-HT3 receptor, approximately 10-fold
greater than the Ki value for displacement of α7 binding.
In several animal models of cognition pertinent to AD,
administration of ABT-126 resulted in signals of efficacy
[10]. The safety and pharmacokinetic characteristics of
ABT-126 were evaluated in single-dose and multiple-
dose phase 1 studies that included healthy adults,
healthy older subjects, clinically stable subjects with
schizophrenia, and subjects with AD. Doses up to 150
mg once daily (QD) or up to 40 mg twice a day were
generally well tolerated (unpublished data).In a previously completed randomized, double-blind,
phase 2a proof-of-concept study, 274 subjects with mild-
to-moderate AD were treated for 12 weeks with 5 mg or
25 mg of ABT-126 QD, placebo, or donepezil [11]. The
change from baseline to the final evaluation in the 11-
item Alzheimer’s Disease Assessment Scale—Cognitive
subscale (ADAS-Cog) [12, 13] total score was the pri-
mary endpoint. The ABT-126 25 mg dose showed some
procognitive effect (ADAS-Cog least squares (LS) mean
(standard error) difference from placebo −1.19 (0.90);
one-sided P = 0.095) which was numerically less effective
than that seen with donepezil treatment (−1.43 (0.90);
one-sided P = 0.057). The 5 mg dose of ABT-126 had an
effect similar to placebo. There was no imbalance in ad-
verse events (AEs) across treatment groups or other
safety signals that would preclude further investigation.
A plateau of ABT-126 efficacy could not be character-
ized based on the exposure–response analysis of the
phase 2a study with a limited dose range of 5–25 mg,
suggesting that testing of higher ABT-126 doses was
needed to definitively characterize the procognitive po-
tential. Additional toxicology and phase 1 data enabled
testing higher doses. Therefore, this 24-week, random-
ized, double-blind, controlled phase 2b study was de-
signed to evaluate a higher dose range of ABT-126 25
mg, 50 mg, and 75 mg QD in subjects with mild-to-
moderate AD.
An adaptive design was chosen to achieve study objec-
tives using a smaller sample size than a more traditional
parallel group design. The study consisted of two parts,
each with its own objectives. The objective of Part 1 was
to efficiently characterize the dose–response relationship
of ABT-126 using a response-adaptive randomization
methodology. The objective of Part 2 was to provide
additional safety data and efficacy data for less sensitive
outcome measures (e.g., quality of life measurements)
for the dose selected in Part 1. This efficient design had
adequate power to characterize the dose–response rela-
tionship on the primary outcome measures (ADAS-Cog)
with a smaller sample size in Part 1. Results from the
double-blind 24-week trial and its 28-week open-label
extension study are reported.
Methods
Subjects
Eligible subjects were 55–90 years of age and diagnosed
with mild-to-moderate AD, defined as meeting National
Institute of Neurological and Communicative Disorders
and Stroke/Alzheimer’s Disease and Related Disorders
Association (NINCDS/ADRDA) criteria for probable
AD. Other key inclusion criteria were a Mini-Mental
Status Examination (MMSE) [14] score of 10–24 (inclu-
sive), a Cornell Scale for Depression in Dementia
(CSDD) [15] score ≤ 10, and a Modified Hachinski
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Subjects who were currently receiving medication for
AD or had taken such agents within 60 days of the first
screening visit were excluded.
The protocol and informed consent were approved by
institutional review boards or independent ethics com-
mittees (Additional file 1). Written informed consent
was obtained from each subject and caregiver prior to
study participation.Study design and treatment
Double-blind study
This was a randomized, double-blind, placebo and active
controlled phase 2b study conducted to evaluate a range
of ABT-126 doses as monotherapy in subjects with
mild-to-moderate AD. The study consisted of two parts,
each 24 weeks in duration with its own goals and
randomization scheme. Part 1 of the study was designed
to investigate the dose–response relationship for three
doses of ABT-126 on the primary endpoint, the 11-item
ADAS-Cog total score. A donepezil arm was included in
Part 1 to permit comparisons of treatment effects of
ABT-126 with a positive control and, ultimately, to verify
assay sensitivity of the design and conduct of the study.
The selected dose from Part 1 was continued into Part 2
to provide additional safety and efficacy data on other
less sensitive outcome measures.
In Part 1, subjects were randomized to placebo, ABT-
126 25 mg, ABT-126 50 mg, ABT-126 75 mg, or done-
pezil, identical in appearance. The first 100 subjects were
randomized with equal probability to the five treatment
arms. Subsequently, the randomization ratio for the
three ABT-126 dose groups changed using a response-
adaptive randomization design in which interim efficacy
data were utilized to change ABT-126 treatment allo-
cation probabilities from the initial 1:1:1 to favor the
more efficacious ABT-126 dose group(s). A detailed
description of the adaptive randomization is provided
in Additional file 2.
For Part 2, the Data Monitoring Committee (DMC)
selected a dose for further evaluation based on the effi-
cacy and safety profile displayed in Part 1. In Part 2 sub-
jects were randomized 1:1 to the selected ABT-126 dose
or placebo. This allowed for a larger sample size for the
selected dose group and the placebo group to evaluate
the effect on secondary measures such as the Clinician
Interview-Based Impression of Change (CIBIC) and
Alzheimer’s Disease Cooperative Study—Activities of
Daily Living (ADCS-ADL) that were expected to have
lower effect sizes than the ADAS-Cog. Part 2
randomization was to continue until 100 subjects (total
from Parts 1 and 2) were randomized to the selected
ABT-126 dose group. In both parts, subjects wereassigned to treatment using an interactive voice re-
sponse/interactive Web-based system.
Assessments in the double-blind study
Efficacy
In the double-blind study, baseline was defined as the
last assessment taken on or before the day −1 study visit.
The 11-item ADAS-Cog was assessed at weeks 4, 8, 12,
18, and 24. The primary efficacy endpoint was the 11-
item ADAS-Cog at week 24. The ADAS-Cog 13-item
total score was analyzed as a secondary efficacy variable.
Other secondary efficacy measures were as follows:
MMSE [14], CIBIC-Plus [17], Neuropsychiatric Inven-
tory (NPI) [18, 19], ADCS-ADL [20], Wechsler Memory
Scale—III (WMS-III) Working Memory Index [21], DE-
Mentia Quality of Life (DEMQOL) [22], Partner–Patient
Questionnaire for Shared Activities (PPQSA) [23], Re-
source Use in Dementia (RUD-Lite) [24], EuroQol-5D-5 L
(EQ-5D-5 L) [25], and EuroQol-5D-3 L (EQ-5D-3 L)
proxy. The timing of secondary efficacy assessments in
the double-blind study is provided in Additional file 3.
Safety
In the double-blind study, the safety of ABT-126 was
assessed through AE monitoring, concomitant medica-
tion review, vital signs, electrocardiograms (ECGs), phys-
ical examinations, brief neurological examinations, brief
psychiatric assessments, Columbia-Suicide Severity
Rating Scale (C-SSRS) [26], and clinical laboratory tests
at each study visit and the CSDD at baseline and at the
week 24/final visit. Telephone contacts conducted dur-
ing weeks 6, 10, 15, and 21 and follow-up assessed AEs
and concomitant medications. In addition, an independ-
ent DMC reviewed safety data throughout the double-
blind trial.
Pharmacokinetic
A pharmacokinetic sample was obtained at each of the
week 2, 4, 8, 12, 18, and 24/early discontinuation study
visits. The dates and times of the previous dose of study
drug and sample collection were recorded. ABT-126
plasma concentrations were determined using a vali-
dated liquid chromatography method with mass spectro-
metric detection at AbbVie (North Chicago, IL, USA).
Medication compliance
Pill counts were used to assess compliance with study
drug at each study visit during the treatment period.
Subjects taking ≥70 % of the study drug were considered
compliant.
Statistical analysis
All randomized subjects from Parts 1 and 2 who took ≥1
dose of study drug were combined and included in the
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one-sided tests at the significance level of 0.050 were uti-
lized to evaluate the treatment effect for each ABT-126
dose group compared with placebo because ABT-126
had to demonstrate improvement over placebo to be
considered effective. For the selected dose group and
placebo, data from Parts 1 and 2 were combined to per-
form statistical analyses without multiplicity adjustment
given the fact that this was a phase 2 study with data
collected to inform the development plan for ABT-126.
Efficacy analyses were conducted using the ITT data-
set and safety analyses on the safety dataset unless other-
wise noted. The change from baseline to week 24 on the
ADAS-Cog 11-item total score was the primary efficacy
variable. The primary efficacy analysis used a likelihood-
based, mixed-effects model for repeated measures
(MMRM) that included fixed, categorical effects for
treatment, site, visit, and treatment-by-visit interaction,
with continuous fixed covariates for baseline score and
the baseline score-by-visit interaction.
The ADAS-Cog 13-item total score, MMSE, NPI,
ADCS-ADL, WMS-III Working Memory Index, DEM-
QOL, and PPQSA were analyzed by MMRM using the
model described for the ADAS-Cog 11-item total score.
Changes from baseline to final observation for variables
RUD-Lite, EQ-5D-5 L, and EQ-5D-3 L proxy were ana-
lyzed by ANCOVA models with treatment and study site
as the main effects and the baseline value as a covariate.
Postbaseline CIBIC-Plus observations were analyzed by
MMRM with the fixed effects of treatment, study site, visit,
and treatment-by-visit interaction, with the Clinician
Interview-Based Impression of Severity (CIBIS) score
collected at day –1 as a covariate.
No adjustment for multiple comparisons was made for
this phase 2 study with the primary objective being
evaluating each ABT-126 dose relative to placebo.
Subgroup analyses were also conducted as described in
Additional file 4.
Analyses of treatment differences between each
ABT-126 dose group and placebo as well as between
donepezil and placebo were conducted for laboratory
measurements, vital sign parameters, and ECG vari-
ables using an ANOVA with treatment as the factor.
Statistical significance for safety variables was judged
at a two-sided test significance level of 0.05.
Open-label extension study
Medically stable subjects could enroll in the extension
study if they completed the double-blind study. Subjects
were treated with ABT-126 75 mg QD for up to 28
weeks, with dosing reductions of 25 mg increments
allowed for safety or tolerability reasons. Study visits oc-
curred on day –1 and weeks 2, 4, 8, 16, and 28 with tele-
phone contacts at weeks 12, 20, and 24 and follow-up(30 days after the last dose of study drug). The safety
and tolerability of ABT-126 was evaluated by AE moni-
toring, concomitant medication review, vital signs,
ECGs, physical examinations, brief neurological exami-
nations, brief psychiatric assessments, C-SSRS, and clin-
ical laboratory tests at each study visit and the CSDD at
baseline and the week 28/final visit. Telephone contacts
assessed AEs and concomitant medications.
Results
Subjects
The study was conducted at 33 sites from February 2012
through December 2013. A total of 557 subjects were
screened and 438 subjects (78.6 %) were randomized in
Russia (n = 153), South Africa (n = 95), the United
Kingdom (n = 65), Ukraine (n = 50), Poland (n = 39), and
the United States (n = 36). Two randomized subjects did
not take the study drug.
Interim adaptation of randomization began after 100
subjects had been randomized. Randomization probabil-
ities were updated every 2 weeks based on cumulative
efficacy information throughout the study (Additional
file 2). At the final analysis in Part 1, subjects were
distributed across treatment dose groups as follows: 60
placebo, 77 ABT-126 25 mg, 64 ABT-126 50 mg, 73
ABT-126 75 mg, and 76 donepezil. When 330 subjects
were enrolled, the Efficacy DMC reviewed the interim
results, including simulation data, effect size calcula-
tions, and safety/tolerability information from the Safety
DMC, and recommended that the trial proceed to Part 2
using ABT-126 50 mg. In Part 2, 88 additional subjects
were enrolled, 40 to ABT-126 50 mg and 48 to placebo,
resulting in a total of 104 subjects in the placebo group
and 108 in the 50 mg group.
Demographic and baseline characteristics are pre-
sented in Table 1. No statistically significant differences
were observed among treatment groups. Approximately
30 % of subjects had taken drugs for AD before the en-
tering the study, most frequently AD medications in the
“Other” category (14.7 %; e.g., piracetam, bapineuzemab,
and other investigational agents), donepezil (7.1 %), gal-
antamine (6.9 %), and memantine (6.0 %).
Subject disposition is presented in Fig. 1. A total of
367 subjects (84.2 %) completed the double-blind study
and 69 subjects (15.8 %) discontinued prematurely. Rates
of early discontinuation were similar across treatment
groups. The most frequently reported reasons for leaving
the study were withdrawn consent (n = 35, 8.0 %) and
AEs (n = 20, 4.6 %).
Efficacy
Twenty-nine subjects were not included in the primary
efficacy analysis because they did not have a baseline or
ontreatment ADAS-Cog 11-item total score (n = 27) or
Table 1 Baseline demographic characteristics in the double-blind controlled study
Placebo ABT-126
25 mg
ABT-126
50 mg
ABT-126
75 mg
Donepezil
10 mg
All subjects
Number of subjects 104 77 107 73 75 436
Age (years), mean ± SD 73.2 ± 7.39 73.0 ± 7.62 73.9 ± 8.26 76.2 ± 8.14 75.1 ± 7.75 74.2 ± 7.89
Age < 75 years, n (%) 59 (56.7) 37 (48.1) 50 (46.7) 30 (41.1) 30 (40.0) 206 (47.2)
Age ≥ 75 years, n (%) 45 (43.3) 40 (51.9) 57 (53.3) 43 (58.9) 45 (60.0) 230 (52.8)
Female, n (%) 65 (62.5) 40 (51.9) 68 (63.6) 52 (71.2) 40 (53.3) 265 (60.8)
Male, n (%) 39 (37.5) 37 (48.1) 39 (36.4) 21 (28.8) 35 (46.7) 171 (39.2)
White, n (%) 91 (87.5) 75 (97.4) 96 (89.7) 64 (87.7) 70 (93.3) 396 (90.8)
BMI (kg/m2), mean ± SD 26.2 ± 3.88 27.1 ± 4.91 26.0 ± 4.98 25.5 ± 4.62 25.0 ± 4.27 26.0 ± 4.57
Age at AD symptom onset (years), mean ± SD 69.6 ± 7.66 69.2 ± 8.51 70.2 ± 8.67 72.3 ± 7.97 71.2 ± 8.24 70.4 ± 8.25
Years since AD symptom onset,a mean ± SD 3.7 ± 2.61 4.1 ± 2.96 3.9 ± 3.11 4.2 ± 2.67 4.2 ± 2.45 4.0 ± 2.78
Age at AD diagnosis (years), mean ± SD 72.1 ± 7.60 71.5 ± 8.10 72.5 ± 8.64 74.8 ± 8.30 73.6 ± 7.91 72.8 ± 8.16
Years since AD diagnosis, mean ± SD 1.1 ± 1.79 1.5 ± 1.91 1.4 ± 2.37 1.5 ± 1.96 1.6 ± 1.92 1.4 ± 2.02
Family history of AD, n (%) 22 (21.2) 20 (26.0) 23 (21.5) 6 (8.2 %) 10 (13.3) 81 (18.6)
ADAS-Cog (11-item),b mean ± SD 26.1 ± 10.98 24.6 ± 11.45 25.6 ± 11.32 27.2 ± 9.81 27.9 ± 12.08 26.2 ± 11.16
MMSE score, mean ± SD 19.1 ± 4.00 20.0 ± 4.09 18.6 ± 4.03 18.6 ± 3.87 18.4 ± 4.42 18.9 ± 4.09
Number of subjects 92 66 97 63 64 382
APOE ε4 positive, n (%) 37 (40.2) 34 (51.5) 48 (49.5) 27 (42.9) 32 (50.0) 178 (46.6)
aTime from onset of AD symptoms or diagnosis to first dose of study drug
bBaseline results based on a total of 435 subjects
AD Alzheimer’s dementia, ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive subscale, APOE apolipoprotein E, BMI body mass index, MMSE Mini-Mental
Status Examination, SD standard deviation
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significant improvement over placebo from baseline
to week 24 in ADAS-Cog 11-item total score was ob-
served for any of the ABT-126 treatment groups
(Fig. 2). LS mean differences from placebo at week 24
were –0.47 for ABT-126 25 mg (90 % CI −2.02, 1.08;
one-sided P = 0.309), –0.87 for ABT-126 50 mg (90 %
CI −2.27, 0.53; P = 0.153), and –1.08 for ABT-126 75
mg (90 % CI −2.63, 0.48; P = 0.127). The donepezil
group demonstrated statistically significant improve-
ment compared with placebo from baseline to week
24 in the ADAS-Cog 11-item total score (LS mean
difference from placebo −2.29, 90 % CI −3.87, −0.72;
P = 0.008).
A prespecified Bayesian dose–response analysis of the
change from baseline to final analysis in the ADAS-Cog
11-item total score using the Part 1 ITT dataset indi-
cated that ABT-126 50 mg and ABT-126 75 mg were
more efficacious than ABT-126 25 mg but less effective
than donepezil. Changes from baseline to week 24 for
the ADAS-Cog 11-item total score from the Part 1 ITT
dataset were also analyzed using an MMRM similar to
that used in the primary analysis. Findings were consist-
ent with the Bayesian dose–response analysis.
MMRM results for the change from baseline to week
24 for secondary efficacy measures are presented inTable 2. Results from an MMRM analysis of the ADAS-
Cog 13-item total score change from baseline to each
study visit were consistent with the ADAS-Cog 11-item
scale results, because no dose of ABT-126 demonstrated
a statistically significant improvement compared with
placebo. Secondary efficacy analyses of the ADAS-Cog
13-item and ADAS-Cog (Items 1, 4, and 8) total scores
were consistent with those observed with the ADAS-
Cog 11-item scale.
Statistically significant improvements in the LS mean dif-
ference from placebo at week 24 were seen on the CIBIC-
Plus for ABT-126 75 mg (–0.38, 90 % CI −0.59, −0.16;
P = 0.002) and for donepezil (–0.43, 90 % CI −0.65, −0.21;
P < 0.001). A Cochran–Mantel–Haenszel analysis of the
CIBIC-Plus also showed significant treatment effects for
ABT-126 75 mg (P = 0.009) and donepezil (P = 0.003) at
week 24.
Significant improvements in the LS mean difference
compared with placebo at week 24 were seen on the
ADCS-ADL total score for ABT-126 50 mg (2.30, 90 %
CI 0.60, 4.01; P = 0.013) and donepezil (4.01, 90 % CI
2.09, 5.93; P < 0.001); trends were observed for both
ABT-126 25 mg and ABT-126 75 mg (P = 0.053 and
P = 0.054, respectively). Compared with placebo, the
basic ADCS-ADL total score had statistically signifi-
cant differences for all treatment groups at week 24
Fig. 1 Study design and subject disposition
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score showed statistically significant differences for
ABT-126 50 mg (P = 0.039) and donepezil (P = 0.001)
at week 24.Using the ANCOVA model, statistically significant dif-
ferences for all treatment groups at the final evaluation
were seen in RUD-Lite caregiver time compared with
placebo, but these differences were attributed to outlier
Fig. 2 LS mean change from baseline over time in 11-item ADAS-Cog total score. Maximum likelihood, mixed-effect, repeated-measures analysis
of change from baseline at each study visit for the ADAS Cog 11-item total score (ITT dataset). Standard error of the LS means represented by
error bars. ADAS-Cog Alzheimer’s Disease Assessment Scale—Cognitive subscale, LS least squares
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maximum number of 720 reportable caregiver hours
(range: –206 to 2347 hours). No statistically significant
differences were observed at the final evaluation in other
secondary measures (MMSE, NPI, WMS-III, DEMQOL,
PPQSA, EQ-5D-5 L, and EQ-5D-3 L proxy) when
ABT-126 dose groups were compared with placebo.
Results from subgroup analyses demonstrated some
modest treatment effects for ABT-126 that did not
surpass the magnitude of effect shown by donepezil. Sta-
tistically significant treatment by subgroup interactions for
country (P = 0.005), baseline age category (P = 0.041), and
baseline MMSE category (P = 0.006) were observed in
ADAS-Cog 11-item total score subgroup analyses
(Additional file 4).Safety
AEs are summarized in Table 3. Of the 436 randomized
and treated subjects, 245 (56.2 %) had at least one AE.
The rates of reported AEs were generally similar among
treatment groups (Table 3). Most AEs (95.5 %) were
assessed by the investigator as mild or moderate in sever-
ity. Urinary tract infection was the only severe AE experi-
enced by more than one subject (one subject receiving
ABT-126 50 mg and one subject receiving placebo).
Constipation occurred in a significantly higher pro-
portion of subjects administered ABT-126 (10.1 %
combined and 15.0 % for 50 mg) compared with pla-
cebo (2.9 %; P = 0.019 and P = 0.003, respectively). Of
the 26 subjects taking ABT-126 who had an AE of
constipation, 17 cases (65.4 %) were considered mild,
Table 2 Double-blind secondary efficacy: change from baseline to final analysis from repeated-measures analyses
Baseline Week 24, n Change from BL to week 24 Difference from placebo
n Observed mean (SD) Mean (SD) LS mean ± SE LS mean ± SE 90 % CI P value
Alzheimer’s Disease Assessment Scale—Cognitive subscale, 13-item total score (↓ indicates improvement)
Placebo 98 38.26 (12.66) 88 −0.76 (6.99) −0.67 ± 0.71
ABT-126 25 mg 71 35.05 (13.06) 63 −1.41 (6.82) −1.14 ± 0.84 −0.47 ± 1.08 −2.25, 1.31 0.333
ABT-126 50 mg 100 36.71 (12.52) 87 −2.12 (6.41) −1.70 ± 0.71 −1.03 ± 0.98 −2.65, 0.60 0.149
ABT-126 75 mg 68 39.11 (10.72) 61 −2.32 (6.07) −1.87 ± 0.84 −1.19 ± 1.09 −2.98, 0.60 0.137
Donepezil 68 39.18 (14.13) 59 −3.56 (6.69) −3.54 ± 0.87 −2.86 ± 1.10 −4.67, −1.05 0.005*
Mini-Mental Status Examination score (↑ indicates improvement)
Placebo 98 18.97 (4.01) 89 0.56 (2.83) 0.39 ± 0.32
ABT-126 25 mg 72 20.08 (4.04) 64 0.19 (3.13) −0.16 ± 0.38 −0.55 ± 0.49 −1.36, 0.27 0.866
ABT-126 50 mg 102 18.70 (3.92) 92 0.86 (3.38) 0.78 ± 0.32 0.39 ± 0.44 −0.34, 1.12 0.191
ABT-126 75 mg 69 18.39 (3.88) 62 0.74 (3.17) 0.53 ± 0.38 0.14 ± 0.49 −0.68, 0.95 0.390
Donepezil 69 18.59 (4.42) 59 1.29 (2.76) 1.19 ± 0.39 0.80 ± 0.50 −0.02, 1.62 0.055
Clinician Interview-Based Impression of Severity and Clinician Interview-Based Impression of Change—Plusa
Placebo 98 3.64 (0.79) 89 4.15 (0.83) 4.18 ± 0.09
ABT-126 25 mg 73 3.77 (0.86) 64 4.03 (0.73) 4.06 ± 0.10 −0.12 ± 0.13 −0.33, 0.10 0.184
ABT-126 50 mg 102 3.63 (0.87) 92 3.95 (0.87) 4.03 ± 0.08 −0.15 ± 0.12 −0.34, 0.05 0.105
ABT-126 75 mg 68 3.75 (0.82) 61 3.77 (0.84) 3.80 ± 0.10 −0.38 ± 0.13 −0.59, −0.16 0.002*
Donepezil 69 3.88 (0.81) 59 3.68 (0.78) 3.75 ± 0.10 −0.43 ± 0.13 −0.65, −0.21 <0.001*
Neuropsychiatric Inventory, 10-item total score (↓ indicates improvement)
Placebo 98 8.64 (8.70) 89 0.18 (6.27) −0.26 ± 0.82
ABT-126 25 mg 73 9.21 (8.93) 64 −1.72 (7.81) −1.09 ± 0.96 −0.82 ± 1.23 −2.86, 1.21 0.252
ABT-126 50 mg 102 8.30 (8.07) 93 −0.59 (9.78) −0.50 ± 0.81 −0.24 ± 1.11 −2.07, 1.60 0.416
ABT-126 75 mg 69 10.57 (11.31) 62 −0.98 (7.26) −0.13 ± 0.96 0.14 ± 1.25 −1.92, 2.19 0.544
Donepezil 69 12.39 (11.63) 59 −3.27 (9.87) −2.72 ± 0.99 −2.45 ± 1.26 −4.53, −0.38 0.026*
Neuropsychiatric Inventory, 12-item total score (↓ indicates improvement)
Placebo 98 10.17 (9.66) 89 0.30 (7.67) −0.11 ± 0.95
ABT-126 25 mg 73 11.19 (10.45) 64 −1.91 (9.84) −0.92 ± 1.11 −0.81 ± 1.44 −3.17, 1.56 0.287
ABT-126 50 mg 102 9.43 (8.55) 93 −0.03 (11.12) 0.05 ± 0.94 0.16 ± 1.30 −1.98, 2.30 0.549
ABT-126 75 mg 69 12.19 (12.93) 62 −1.52 (8.01) −0.54 ± 1.12 −0.43 ± 1.45 −2.82, 1.96 0.383
Donepezil 69 13.41 (12.77) 59 −3.10 (10.82) −2.67 ± 1.15 −2.55 ± 1.46 −4.96, −0.15 0.041*
Alzheimer’s Disease Cooperative Study—Activity of Daily Living total score (↑ indicates improvement)
Placebo 98 56.46 (14.17) 89 −1.79 (8.16) −2.30 ± 0.76
ABT-126 25 mg 73 57.15 (16.35) 64 0.28 (6.65) −0.44 ± 0.89 1.86 ± 1.14 −0.03, 3.74 0.053
ABT-126 50 mg 102 55.97 (14.96) 93 0.18 (7.13) 0.00 ± 0.75 2.30 ± 1.04 0.60, 4.01 0.013*
ABT-126 75 mg 69 54.30 (14.65) 62 −0.21 (7.18) −0.44 ± 0.90 1.86 ± 1.15 −0.04, 3.76 0.054
Donepezil 69 52.00 (14.11) 59 2.14 (5.60) 1.71 ± 0.92 4.01 ± 1.16 2.09, 5.93 <0.001*
Baseline Week 18, n Change from BL to week 18 Difference from placebo
n Observed mean (SD) Mean (SD) LS mean ± SE LS mean ± SE 90 % CI P value
Wechsler Memory Scale—III Working Memory Index total score (↑ indicates improvement)
Placebo 93 74.02 (13.28) 91 2.04 (11.21) 1.17 ± 1.11
ABT-126 25 mg 68 78.50 (17.02) 65 0.83 (11.38) 0.24 ± 1.31 −0.93 ± 1.64 −3.63, 1.77 0.715
ABT-126 50 mg 99 75.57 (13.40) 93 −0.42 (11.32) −1.73 ± 1.10 −2.91 ± 1.48 −5.34, −0.47 0.975
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Table 2 Double-blind secondary efficacy: change from baseline to final analysis from repeated-measures analyses (Continued)
ABT-126 75 mg 66 77.85 (15.40) 64 −1.66 (10.66) −2.34 ± 1.27 −3.52 ± 1.65 −6.23, −0.80 0.983
Donepezil 61 75.66 (15.54) 61 1.82 (8.88) 1.31 ± 1.35 0.13 ± 1.65 −2.60, 2.86 0.468
*One-sided P value statistically significant vs placebo
aClinician Interview-Based Impression of Severity at baseline and Clinician Interview-Based Impression of Change—Plus at subsequent visits. Clinician Interview-
Based Impression of Change—Plus ratings range from 1 =markedly improved to 7 =markedly worse. LS means (SE) are presented instead of LS mean (SE)
of change
BL baseline (last assessment taken on or before the day –1 visit), LS least squares, SD standard deviation, SE standard error
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(3.8 %) was severe.
Twenty-seven subjects (6.2 %) discontinued from the
study prematurely because of an AE (Table 3). Constipation
was the only AE leading to discontinuation in more than
one subject taking ABT-126 (one subject receiving ABT-126
25 mg and two subjects receiving ABT-126 50 mg). Signifi-
cantly more subjects in the donepezil group discontinued
prematurely for any AE compared with placebo (P= 0.045).
This finding appeared to be driven by three donepezil-
treated subjects (4.0 %) who left the study due to gastro-
intestinal disorders.
The frequency of serious adverse events (SAEs) was
similar across treatment groups, occurring in 23 subjects
(5.3 %) overall (Table 3). Constipation and urinary tract
infection were the only SAEs that occurred in more thanTable 3 Summary of treatment-emergent adverse events from both
Double-blind study
Placebo
(n = 104)
ABT-126 25 mg
(n = 77)
ABT-126 5
(n = 107)
Any AE 56 (53.8) 42 (54.5) 62 (57.9)
Possibly relateda 20 (19.2) 16 (20.8) 27 (25.2)
Discontinued due to AE 4 (3.8) 5 (6.5) 7 (6.5)
Severe AE 2 (1.9) 3 (3.9) 2 (1.9)
Serious AE 5 (4.8) 6 (7.8) 7 (6.5)
Deathsb 0 0 0
AEs reported by ≥ 5.0 % of subjects in any treatment group in the double-bl
Constipatione 3 (2.9) 7 (9.1) 16 (15.0)e
Headache 7 (6.7) 5 (6.5) 4 (3.7)
Fall 4 (3.8) 4 (5.2) 5 (4.7)
Nausea 3 (2.9) 1 (1.3) 4 (3.7)
Diarrhea 2 (1.9) 2 (2.6) 4 (3.7)
Anxiety 1 (1.0) 1 (1.3) 7 (6.5)
Depressed mood 1 (1.0) 1 (1.3) 0
aAny AE determined by the investigator as having a reasonable possibility of being
bIncludes all deaths, whether or not considered treatment emergent. In both studie
possibility of being related to the study drug
cCerebrovascular accident (day 6) and septic shock (day 143)
dAdvanced age (open-label extension day 7); cerebral infarction, brain edema, brain
thrombosis and gastrointestinal necrosis (open-label extension day 21); and myocar
eStatistically significant vs placebo (P = 0.0019 for ABT-126 combined and P = 0.003
All data are presented as n (%)
AE adverse event, MedDRA Medical Dictionary for Regulatory Activities, n number oone subject taking ABT-126 (two subjects each). Two
deaths occurred during the study, both in the donepezil
group. One subject experienced a cerebrovascular acci-
dent on day 3, was hospitalized, and died 3 days later.
Another subject died of septic shock on day 143, 1 day
after being hospitalized for cholelithiasis. Both events
were judged by the investigator as having no reasonable
possibility of being related to the study drug.
No consistent clinically meaningful mean changes or
dose-related trends were detected in laboratory, vital
signs, ECG findings, CSDD total scores, and C-SSRS for
any group in the double-blind study.
Pharmacokinetic
ABT-126 concentrations were consistent with the ex-
pected plasma concentrations based on previousstudies, n (%)
Open-label study
0 mg ABT-126 75 mg
(n = 73)
Donepezil 10 mg
(n = 75)
ABT-126 75 mg
(n = 349)
38 (52.1) 47 (62.7) 167 (47.9)
14 (19.2) 24 (32.0) 66 (18.9)
2 (2.7) 9 (12.0) 13 (3.7)
1 (1.4) 3 (4.0) 18 (5.2)
2 (2.7) 3 (4.0) 17 (4.9)
0 2 (2.7)c 4 (1.1)d
ind study (MedDRA preferred term)
3 (4.1) 2 (2.7) 17 (4.9)
5 (6.8) 8 (10.7) 11 (3.2)
3 (4.1) 5 (6.7) 15 (4.3)
2 (2.7) 6 (8.0) 7 (2.0)
2 (2.7) 4 (5.3) 6 (1.7)
2 (2.7) 0 6 (1.7)
0 4 (5.3) 3 (0.9)
related to the study drug
s all events related to deaths were considered as having no reasonable
stem syndrome, and pulmonary edema (open-label extension day 40); arterial
dial infarction (open-label extension day 172)
for ABT-126 50 mg)
f subjects
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subjects with AD. In this trial, the percentage of subjects
with consistently (on three or more visits) low plasma
concentrations (below the minimum simulated for each
dose level) was approximately 4 % across the ABT-126
dose levels, suggesting that a high percentage of the sub-
jects (approximately 96 %) had reasonable compliance
with the study drug.
Medication compliance
Overall 93.8 % of subjects in the double-blind study
were considered by the investigator to be compliant with
the study drug at least 70 % of the time. A significantly
smaller proportion of subjects taking donepezil were
treatment compliant at week 4 (92.8 %; P = 0.005) com-
pared with the other treatment groups (ABT-126 25 mg,
100 %; ABT-126 50 mg, 99.0 %; ABT-126 75 mg, 98.5 %;
placebo, 100 %); this difference was not observed in sub-
sequent weeks.
Open-label extension study
A total of 349/367 subjects (95.1 %) who completed the
double-blind study enrolled into the open-label exten-
sion study (62 ABT-126 25 mg, 86 ABT-126 50 mg, 57
ABT-126 75 mg, 87 placebo, 57 donepezil). The open-
label extension study was terminated early following
completion of the double-blind study because ABT-126
did not demonstrate adequate efficacy in two random-
ized phase 2 studies. No efficacy analyses were con-
ducted. A total of 183 subjects (52.4 %) completed the
study and 166 subjects (47.6 %) discontinued the study
prematurely—129 discontinuations (77.7 %) were due to
the termination of the study (Fig. 1). Thirteen subjects
(3.7 %) discontinued prematurely due to an AE.
Participating in the open-label study were 210 females
(60.2 %) and 139 males (39.8 %), with a mean age of 74.1
years; 90.0 % were white. The baseline mean (SD)
MMSE total score was 19.7 (5.00). All subjects took
at least one dose of ABT-126 75 mg. Twelve subjects
(3.4 %) had decreased to ABT-126 50 mg QD, and
one subject increased back to ABT-126 75 mg QD.
During the open-label study 167 subjects (47.9 %) re-
ported at least one AE. The most frequently reported
AEs were constipation (4.9 %), fall (4.3 %), headache
(3.2 %), agitation (2.3 %), irritability (2.3 %), and nau-
sea (2.0 %; Table 3). Approximately 90 % of the AEs
were considered mild or moderate in severity, and 18
subjects (10.8 %) experienced a severe AE. A total of
66 subjects (18.9 %) had an AE assessed by the inves-
tigator as having a reasonable possibility of being re-
lated to the study drug.
SAEs were experienced by 17 subjects (4.9 %). Con-
vulsion (three subjects, 0.9 %) and femoral neck frac-
ture (two subjects, 0.6 %) were the only SAEs reportedby ≥ 2 subjects. One SAE of convulsion was considered
as having a reasonable possibility of being related to
the study drug.
There were four deaths during the study: myocardial
infarction (open-label extension day 172); advanced age
(open-label extension day 7); cerebral infarction, brain
edema, brain stem syndrome, and pulmonary edema
(open-label extension day 40); and arterial thrombosis
and gastrointestinal necrosis (open-label extension day
21). All events leading to the deaths were considered by
the investigator as having no reasonable possibility of
being related to the study drug. Similar to the double-
blind study, no clinically significant trends were identi-
fied in laboratory results, vital signs, ECG findings,
CSDD total scores, and C-SSRS.
Discussion
In this randomized double-blind trial of multiple doses
of ABT-126, none of the ABT-126 groups had statisti-
cally significant improvement compared with placebo
from baseline to week 24 on the ADAS-Cog 11-item
total score. The ABT-126 50 mg and ABT-126 75 mg
dose groups showed statistically significant improve-
ments over placebo on the ADCS-ADL and CIBIC-Plus,
respectively, but the improvement was numerically lower
than that observed with donepezil. Similarly, some sub-
group analyses showed a statistically significant improve-
ment over placebo on the ADAS-Cog (e.g., MMSE < 19,
age < 75), but in all cases the magnitude of the treatment
effects observed was smaller than that observed with
donepezil. Treatment with donepezil led to statistically
significant improvements on the ADAS-Cog 11 item
total score, the CIBIC-Plus, and the ADCS-ADL. The re-
sults observed for the donepezil group are consistent
with previous trials [27] and suggest that the design of
the study and its conduct were sufficient to achieve
assay sensitivity for these measures.
The discrepant efficacy results for the ABT-126 75
mg dose observed on the cognition measure and the
secondary measures were unexpected. These results
do not appear to be due to lack of assay sensitivity
on the ADAS-Cog, since the donepezil group demon-
strated an improvement consistent with previous tri-
als, and suggests that the results for the ADCS-ADL
and CIBIC-Plus do not constitute true signals of effi-
cacy for ABT-126.
No serious safety signals were identified for ABT-126
monotherapy in subjects with mild-to-moderate AD in
either the double-blind or extension studies. The overall
rates of AEs and SAEs were similar across treatment
groups in the double-blind study and led to few subjects
discontinuing from the study. There were no consistent
clinically meaningful changes in laboratory, vital sign, or
ECG values in either study.
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tically significant higher percentage of subjects treated
with ABT-126 compared with placebo in the double-
blind study (P = 0.019) and was reported in 17 subjects
in the open-label study. Compared with placebo, a statis-
tically significantly larger proportion of subjects treated
with ABT-126 50 mg had gastrointestinal disorders con-
sidered to have a reasonable possibility of being related
to the study drug (P = 0.033). This finding was likely in-
fluenced by AEs of constipation. The emergence of con-
stipation as the most frequent AE in the double-blind
study, occurring at an incidence that was statistically
higher than placebo, is consistent with information re-
ported by Forum Pharmaceuticals for their α7 agonist,
encenicline, in mild-to-moderate AD [9]. Because of
structural similarities between the α7 nAChR subunit
and the 5HT-3 receptor, α7 agonists can bind to the 5-
HT3 receptor [6, 28, 29]. ABT-126 shows a 10-fold
higher affinity for α7 nAChR relative to the 5-HT3 re-
ceptor, whereas encenicline has approximately equal af-
finity for each receptor type, raising the possibility that
off-target binding to the 5-HT3 receptor binding leads
to constipation.
This study utilized a novel study design that consisted
of an adaptive randomization to efficiently explore the
dose–response relationship across three doses of ABT-
126 compared with placebo and donepezil (Part 1) and
permitted additional exploration of the efficacy and
safety of the selected dose compared with placebo (Part
2). If the study had been powered to evaluate each dose
arm for both primary and secondary measures in a trad-
itional parallel-group design, the sample size would have
increased to at least 100 subjects per arm for a total of
500 subjects. The sample size savings in Part 1 of the
trial with adaptive randomization are related to the slope
of the dose–response curve, with steeper slopes resulting
in differential allocation to the selected dose and shal-
lower slopes resulting in allocation that is roughly
proportionate across dose groups. In this trial, the
dose–response relationship exhibited by ABT-126 did
not result in disproportionate sample size allocation;
thus, the potential sample size savings based on this
feature were not recognized. In simulations of other
types of dose–response curves, such as no effect or
an effect with ABT-126 75 mg that was much greater
than placebo or the active control, a sample size sav-
ing of 227 or 150, respectively, could have been real-
ized for the entire study compared with the parallel
design with 500 subjects. In addition, had the decision
been made not to proceed to Part 2 of the study, the total
sample size could have been further reduced by 88 sub-
jects. To our knowledge, this study is the first adaptive
randomization design to include comparisons with both a
placebo and an active control. Inclusion of an activecontrol can be especially helpful for decision-making, be-
cause it allows the futility and success algorithms to stipu-
late decisions relative to each.
The decision to include adaptive design elements in a
clinical trial needs to be made both with an evaluation of
the potential benefits and an appreciation for the added
complexity inherent in these trials. Designing the
randomization scheme and implementing the Interactive
Voice Response System takes longer for an adaptive trial
than for conventional trial designs. Ongoing data cleaning,
frequent interim evaluations and DMC meetings, and up-
dates to the Interactive Voice Response System are some
of the required activities. Overall, adaptive randomization
is most valuable in dose–response studies with a high
number of dose arms. Potential advantages (such as a
lower sample size) need to be examined on a case-by-case
basis to determine suitability for a particular study.
One limitation of this study is that, consistent with
clinical practice at the time of study execution, the
NINCDS/ADRDA criteria were used for the diagnosis of
AD in study subjects and there was no confirmation of
the presence of cerebral amyloid. Based on neuropatho-
logical analysis of patients meeting diagnostic criteria for
AD [30, 31] and on recent clinical trial results showing
that approximately 30 % of subjects selected with these
criteria have negative positron emission tomography
scans for amyloid [32, 33], we expect that some subjects
in this trial would also be amyloid negative and would
likely not have dementia due to AD. Subjects with other
causes of cognitive impairment may not progress over
time, contributing to a lack of decline in the placebo
group and increasing the difficulty of eliciting a treatment
response. In this trial, the placebo decline on the ADAS-
Cog was larger in the moderate AD subgroup, likely
reflecting both a higher percentage of subjects that are
amyloid positive and a greater degree of sensitivity for the
ADAS-Cog to detect changes in this subgroup, and it was
this subgroup that demonstrated small but statistically sig-
nificant treatment effects. Subgroup analyses investigating
treatment effects by MMSE score, age, gender, country,
and apolipoprotein E status were limited by the number
of subjects included in each subgroup.
In parallel with execution of this monotherapy trial, a
second trial investigating the efficacy and safety of ABT-
126 as an add-on treatment to AChEIs was also con-
ducted. In that trial, 25 mg or 75 mg ABT-126 failed to
demonstrate statistically significant improvement relative
to placebo. There was some evidence in that trial for a po-
tential treatment effect in the subjects with mild AD [34].
This contrasts with the subgroup analysis presented here
for the monotherapy trial where some evidence for effi-
cacy was observed in the moderate AD subpopulation.
Taken together, these data suggest that further exploration
of efficacy in either of these subgroups is not warranted.
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ABT-126 as monotherapy or add-on therapy in mild-
to-moderate AD do not support further development
of this compound. With the two phase 3 studies of
the α7 nAChR partial agonist encenicline (Clinical-
Trials.gov NCT01969123 and NCT01969136) being
placed on clinical hold [9], the future development of
other agents in this class is uncertain.
Conclusions
ABT-126 did not result in statistically significant
improvement in the primary measure of cognition at any
dose. The results obtained with donepezil treatment
indicate that the design and conduct of the study were
sufficient to detect a meaningful treatment difference.
Significant improvement in secondary measures of daily
function and global improvement were seen with ABT-
126 50 mg and ABT-126 75 mg, but the magnitude of
the effect did not support further development of ABT-
126 for the monotherapy treatment of mild-to-moderate
AD. Overall there were no serious safety signals identi-
fied for ABT-126 in subjects with AD.
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